Market Overview

Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.


Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.

Dr. Muenzer to review MPS II biology, standard of care, and rationale for the development of SB-913, an investigational genome editing treatment

Webcast is scheduled for 2 p.m. ET on Wednesday, August 1, 2018

PR Newswire

RICHMOND, Calif., July 27, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced today that the Company will host a webcast to review mucopolysaccharidosis Type II (MPS II, or Hunter syndrome) disease biology, standard of care treatment options, and scientific rationale for the development of SB-913, Sangamo's investigational in vivo genome editing treatment for MPS II. The webcast is scheduled for 2 p.m. Eastern Time on Wednesday, August 1, 2018.

Sangamo Therapeutics, Inc. (PRNewsfoto/Sangamo Therapeutics, Inc.)

The webcast will include a presentation and Q&A session with Joseph Muenzer, M.D., Ph.D., a Professor of Pediatrics and Genetics at the University of North Carolina School of Medicine and an expert in MPS diseases.

The August 1st event will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will be archived on the Sangamo website after the event.

In late summer Sangamo plans to present preliminary data from the Phase 1/2 clinical trial evaluating SB-913 for MPS II ("the CHAMPIONS study").

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit

Forward-Looking Statements

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's plan to present preliminary clinical data from the CHAMPIONS study in late summer.

These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the dependence on the success of clinical trials of lead programs, the lengthy and uncertain regulatory approval process, uncertainties related to the initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of Sangamo's therapeutics, and the reliance on partners and other third-parties to meet their obligations. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.


Cision View original content with multimedia:

SOURCE Sangamo Therapeutics, Inc.

View Comments and Join the Discussion!